Evolution of MET and NRAS Gene Amplification as Acquired Resistance Mechanisms in EGFR Mutant NSCLC

A patient-derived cell line obtained at the time of disease progression was used to identify NRAS gene amplification as an additional driver of drug resistance to combination EGFR/MET therapies.